StocksFundsScreenerSectorsWatchlists
NBIX

NBIX - Neurocrine Biosciences Inc Stock Price, Fair Value and News

132.99USD+1.25 (+0.95%)Market Closed

Market Summary

NBIX
USD132.99+1.25
Market Closed
0.95%

NBIX Alerts

  • 4 major insider sales recently.

NBIX Stock Price

View Fullscreen

NBIX RSI Chart

NBIX Valuation

Market Cap

13.2B

Price/Earnings (Trailing)

53

Price/Sales (Trailing)

7.01

EV/EBITDA

36.62

Price/Free Cashflow

36.6

NBIX Price/Sales (Trailing)

NBIX Profitability

Operating Margin

99.24%

EBT Margin

17.60%

Return on Equity

11.19%

Return on Assets

7.68%

Free Cashflow Yield

2.73%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

1.9B

Rev. Growth (Yr)

25.05%

Rev. Growth (Qtr)

3.29%

NBIX Earnings

Earnings (TTM)

249.7M

Earnings Growth (Yr)

65.96%

Earnings Growth (Qtr)

77.74%

Breaking Down NBIX Revenue

Last 7 days

-5.5%

Last 30 days

-5.3%

Last 90 days

-0.7%

Trailing 12 Months

28.2%

How does NBIX drawdown profile look like?

NBIX Financial Health

Current Ratio

2.45

Debt/Equity

0.08

Debt/Cashflow

2.3

NBIX Investor Care

Shares Dilution (1Y)

3.02%

Diluted EPS (TTM)

2.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.6B1.7B1.8B1.9B
20221.2B1.3B1.4B1.5B
20211.0B1.0B1.1B1.1B
2020886.8M1.0B1.0B1.0B
2019518.6M605.1M675.5M788.1M
2018232.7M323.3M414.3M451.2M
201706.3M67.1M161.6M
201615.0M15.0M15.0M15.0M
201522.0M21.2M20.5M19.8M
201340.6M28.0M15.5M2.9M
201276.2M74.6M42.3M53.1M
201145.3M52.8M80.0M77.4M
2010013.1M23.3M33.5M
20090003.0M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Neurocrine Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
delaet ingrid
sold
-37,345
137
-272
chief regulatory officer
Apr 01, 2024
delaet ingrid
acquired
21,493
79.02
272
chief regulatory officer
Mar 21, 2024
delaet ingrid
acquired
517,600
103
5,000
chief regulatory officer
Mar 21, 2024
delaet ingrid
sold
-725,320
145
-5,000
chief regulatory officer
Mar 14, 2024
morrow george j
sold
-5,576,710
139
-40,000
-
Mar 14, 2024
morrow george j
acquired
795,800
39.79
20,000
-
Mar 14, 2024
benevich eric
acquired
6,067,630
80.9017
75,000
chief commercial officer
Mar 14, 2024
benevich eric
sold
-10,453,400
139
-75,000
chief commercial officer
Mar 13, 2024
delaet ingrid
sold
-420,419
140
-3,000
chief regulatory officer
Mar 13, 2024
pops richard f
acquired
992,032
42.76
23,200
-

1–10 of 50

Which funds bought or sold NBIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
reduced
-20.51
-159,564
790,557
0.02%
Apr 15, 2024
THOMPSON INVESTMENT MANAGEMENT, INC.
reduced
-0.97
37,088
1,051,640
0.16%
Apr 15, 2024
Sunbelt Securities, Inc.
reduced
-10.15
-2,549
40,273
-%
Apr 15, 2024
Pallas Capital Advisors LLC
new
-
338,042
338,042
0.01%
Apr 15, 2024
Portman Square Capital LLP
unchanged
-
10,207
228,533
0.01%
Apr 15, 2024
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
added
48.53
233,451
654,292
-%
Apr 15, 2024
NorthCrest Asset Manangement, LLC
reduced
-5.01
-4,030
706,288
0.02%
Apr 15, 2024
Concurrent Investment Advisors, LLC
new
-
331,904
331,904
0.02%
Apr 12, 2024
FCF Advisors LLC
sold off
-100
-1,157,250
-
-%
Apr 12, 2024
WASHINGTON CAPITAL MANAGEMENT, INC
reduced
-15.79
-74,180
551,680
0.45%

1–10 of 46

Are Funds Buying or Selling NBIX?

Are funds buying NBIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NBIX
No. of Funds

Unveiling Neurocrine Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.88%
9,710,328
SC 13G/A
Jan 23, 2024
blackrock inc.
13.9%
13,647,679
SC 13G/A
Feb 09, 2023
janus henderson group plc
2.5%
2,415,638
SC 13G/A
Feb 09, 2023
vanguard group inc
9.72%
9,340,295
SC 13G/A
Jan 23, 2023
blackrock inc.
13.1%
12,627,403
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
4.5%
4,359,645
SC 13G/A
Feb 10, 2022
vanguard group inc
9.26%
8,787,991
SC 13G/A
Feb 10, 2022
janus henderson group plc
7.8%
7,445,839
SC 13G/A
Jan 27, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A
Jan 26, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A

Recent SEC filings of Neurocrine Biosciences Inc

View All Filings
Date Filed Form Type Document
Apr 15, 2024
144
Notice of Insider Sale Intent
Apr 10, 2024
ARS
ARS
Apr 10, 2024
DEF 14A
DEF 14A
Apr 10, 2024
DEFA14A
DEFA14A
Apr 03, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 21, 2024
144
Notice of Insider Sale Intent
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading

Peers (Alternatives to Neurocrine Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
348.0B
85.2B
-6.73% -11.03%
9.9
4.09
6.46% 95.94%
316.7B
60.1B
3.80% 9.39%
867.76
5.27
1.40% -97.49%
145.1B
46.5B
-7.30% -37.12%
-104.48
3.12
42.59% -114.62%
142.4B
28.2B
-1.26% 6.20%
21.2
5.05
7.09% 2.52%
83.9B
27.1B
-8.06% -18.37%
14.81
3.09
-0.60% 23.36%
14.7B
15.8B
-1.49% 59.59%
-25.47
0.93
6.17% 76.47%
MID-CAP
4.1B
4.7B
-0.79% -17.32%
-321.5
0.88
4.58% 90.97%
4.0B
1.7B
-16.49% -18.19%
11.18
2.39
49.61% 324.78%
3.2B
8.8B
-6.09% 15.35%
-5.39
0.36
7.79% -163.11%
2.0B
644.4M
-5.18% -3.16%
14.31
3.05
29.14% 50.51%
SMALL-CAP
1.4B
743.2M
4.05% -24.05%
-4.05
1.92
24.65% 80.36%
22.1M
70.0M
-17.92% -45.58%
-2.15
0.38
-19.54% -109.18%
17.3M
-
-10.43% 48.74%
-0.94
0.22
2882.68% -138.52%
1.2M
19.6M
-33.33% -94.84%
-0.08
0.06
80.00% 43.08%
496.8K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

Neurocrine Biosciences Inc News

Latest updates
MarketBeat3 hours ago
Investor's Business Daily11 Mar 202407:00 am

Neurocrine Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.3%515499453420412388378311312296289237248259302237244222184138131
Cost Of Revenue----------------2.002.002.00-1.00-
Costs and Expenses2.0%365358379535309300324308348252226205176303226178-132149--
Operating Expenses---------326---176303226178195132149239110
  S&GA Expenses7.2%21920422224318318618320115715514312910711397.0011810185.0081.0088.0069.00
  R&D Expenses------------73.00---58.00--62.0038.0039.00
EBITDA Margin22.7%0.19*0.15*0.15*0.07*0.16*0.08*0.04*0.11*0.12*0.18*0.10*0.13*---------
Interest Expenses0%1.001.001.001.001.001.002.003.007.007.006.006.008.009.008.008.008.008.008.008.008.00
Income Taxes55.4%51.0033.0026.00-26.7029.0029.00-6.408.00-6.508.0015.00-4.90-3061.004.002.005.005.001.00-0.50-
Earnings Before Taxes71.5%198116122-10311898.00-23.3021.00-13.8031.0058.0027.0042.00-57.1083.0039.0039.0058.0052.00-10219.00
EBT Margin24.7%0.18*0.14*0.14*0.06*0.14*0.06*0.01*0.08*0.09*0.15*0.07*0.09*---------
Net Income77.7%14883.0096.00-76.6089.0069.00-16.9014.00-7.3023.0042.0032.00348-57.6080.0037.0034.0054.0051.00-10218.00
Net Income Margin23.6%0.13*0.11*0.11*0.04*0.10*0.04*0.01*0.06*0.08*0.42*0.35*0.38*---------
Free Cashflow-42.2%118204173-133141101129-48.10-4.7056.0099.0083.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets14.2%3,2512,8482,6132,3602,3692,1432,0062,1452,0732,0171,9561,8461,7351,5031,5161,3621,3061,1801,067958993
  Current Assets-2.6%1,6071,6501,4971,4331,4541,2061,0191,0189731,0061,1101,0851,0161,1571,146968831819749633738
    Cash Equivalents-14.5%25129416010426321216327034431136835319042541518711617214778.00147
  Inventory33.0%38.0029.0032.0033.0035.0037.0029.0029.0031.0026.0028.0030.0028.0021.0022.0021.0017.0011.0012.0013.0011.00
  Net PPE2.9%71.0069.0066.0063.0059.0061.0067.0064.0059.0051.0050.0045.0045.0043.0045.0042.0042.0040.0040.0037.0034.00
Liabilities20.5%1,019846760675661599582753699671677641609698684662669605583548512
  Current Liabilities-5.3%65569258337453848528625424622621319018761157314056511610172.0088.00
  Long Term Debt----170--169378335331326322318--414-404398393388
    LT Debt, Current0.1%170170170-169169-------425420-409----
    LT Debt, Non Current----170--169378335331326322318--414-404398393388
Shareholder's Equity11.5%2,2322,0021,8531,6851,7081,5451,4231,3911,3741,3461,2791,2061,126804831700637575484409481
  Retained Earnings48.5%-157-304-387-483-406-495-564-547-635-628-651-693-725-1,073-1,015-1,095-1,132-1,166-1,220-1,271-1,177
  Additional Paid-In Capital3.2%2,3822,3092,2422,1712,1222,0542,0001,9482,0111,9741,9291,8981,8501,8741,8421,7971,7681,7401,7031,6811,660
Shares Outstanding0.5%99.0098.0098.0098.0097.0096.0095.0095.0095.0095.0094.0094.00---------
Float---7,900---8,097---9,105---11,232---5,753--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-41.7%123,500212,000179,600-125,200143,00098,800138,100-40,5004,20061,800103,20087,30094,500-20,400118,90035,50097,50097,80064,200-112,50050,490
  Share Based Compensation-20.3%38,10047,80068,50039,90043,50043,10049,50037,00035,60037,10028,60032,90021,00026,70029,50022,80021,30020,30017,90015,80013,300
Cashflow From Investing-107.4%-201,800-97,300-125,900-42,100-115,600-61,30031,400-31,60023,700-126,200-90,80063,100-147,70025,20093,40033,200-166,200-85,600-30041,000-106,241
Cashflow From Financing88.3%35,40018,8002,9008,20024,60011,400-276,4006,1001,8007,5003,00015,100-185,0005,40015,8006,00012,40013,1004,3002,6001,752

NBIX Income Statement

2023-12-31
Consolidated Statements Income and Comprehensive Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Revenues$ 1,887.1$ 1,488.7$ 1,133.5
Operating expenses:   
Cost of revenues39.723.214.3
Research and development565.0463.8328.1
Acquired in-process research and development143.90.0105.3
Selling, general and administrative887.6752.7583.3
Total operating expenses1,636.21,239.71,031.0
Operating income250.9249.0102.5
Other income (expense):   
Interest expense(4.6)(7.1)(25.8)
Unrealized gain on equity securities28.430.820.9
Loss on extinguishment of convertible senior notes0.0(70.0)0.0
Investment income and other, net57.411.23.8
Total other income (expense), net81.2(35.1)(1.1)
Income before provision for income taxes332.1213.9101.4
Provision for income taxes82.459.411.8
Net income249.7154.589.6
Foreign currency translation adjustments, net of tax2.42.90.0
Unrealized gain (loss) on debt securities available-for-sale, net of tax12.5(9.1)(3.5)
Comprehensive income$ 264.6$ 148.3$ 86.1
Earnings per share, basic (in USD per share)$ 2.56$ 1.61$ 0.95
Earnings per share, diluted (in USD per share)$ 2.47$ 1.56$ 0.92
Weighted average common shares outstanding, basic (in shares)97.795.894.6
Weighted average common shares outstanding, diluted (in shares)101.098.997.9
Net product sales   
Revenues:   
Revenues$ 1,860.6$ 1,440.9$ 1,090.1
Collaboration revenue   
Revenues:   
Revenues$ 26.5$ 47.8$ 43.4

NBIX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 251.1$ 262.9
Debt securities available-for-sale780.5726.4
Accounts receivable, net439.3350.0
Inventory, net38.335.1
Other current assets97.879.1
Total current assets1,607.01,453.5
Deferred tax assets362.6305.9
Debt securities available-for-sale687.5299.4
Right-of-use assets276.587.0
Equity securities161.9102.1
Property and equipment, net70.858.6
Intangible assets, net35.537.2
Other assets49.625.0
Total assets3,251.42,368.7
Current liabilities:  
Accounts payable and accrued liabilities448.8347.6
Convertible senior notes170.1169.4
Other current liabilities35.920.7
Total current liabilities654.8537.7
Noncurrent operating lease liabilities258.393.5
Other long-term liabilities106.329.7
Total liabilities1,019.4660.9
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding0.00.0
Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,382.02,122.4
Accumulated other comprehensive income (loss)7.0(7.9)
Accumulated deficit(157.1)(406.8)
Total stockholders’ equity2,232.01,707.8
Total liabilities and stockholders’ equity$ 3,251.4$ 2,368.7
NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
 CEO
 WEBSITEneurocrine.com
 INDUSTRYPharmaceuticals
 EMPLOYEES1350

Neurocrine Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Mon Apr 15 2024, market cap of Neurocrine Biosciences Inc is 13.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers. The fair value of Neurocrine Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neurocrine Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, NBIX's PE ratio (Price to Earnings) is 52.49 and Price to Sales (PS) ratio is 6.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.256 (multiply by 100 for percentage) rate of return.